These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3281173)

  • 21. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity.
    Ditschuneit HH; Flechtner-Mors M; Dolderer M; Fulda U; Ditschuneit H
    Horm Metab Res; 1993 Nov; 25(11):573-8. PubMed ID: 8288160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of naloxone on prolactin, growth hormone and cortisol response to insulin hypoglycemia in obese subjects.
    Papalia D; Lunetta M; Di Mauro M
    J Endocrinol Invest; 1989 Dec; 12(11):777-82. PubMed ID: 2693516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1988 Mar; 66(3):489-94. PubMed ID: 3127415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired growth hormone response to clonidine in obesity.
    Altomonte L; Zoli A; Mirone L; Berchicci M; Travaglini R; Pellicano P; Greco AV
    Exp Clin Endocrinol; 1988 Dec; 92(2):231-4. PubMed ID: 3243343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
    Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
    Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency.
    Maccario M; Aimaretti G; Grottoli S; Gauna C; Tassone F; Corneli G; Rossetto R; Wu Z; Strasburger CJ; Ghigo E
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1233-9. PubMed ID: 11477509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome due to coexistent obesity.
    Slowinska-Srzednicka J; Zgliczynski W; Makowska A; Jeske W; Brzezinska A; Soszynski P; Zgliczynski S
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1432-5. PubMed ID: 1534330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index.
    Corneli G; Di Somma C; Baldelli R; Rovere S; Gasco V; Croce CG; Grottoli S; Maccario M; Colao A; Lombardi G; Ghigo E; Camanni F; Aimaretti G
    Eur J Endocrinol; 2005 Aug; 153(2):257-64. PubMed ID: 16061832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of fenfluramine and cyproheptadine on growth hormone secretion.
    Mazzi C; Riva LP; Bernasconi D
    Ann Endocrinol (Paris); 1976; 37(5):355-64. PubMed ID: 1020921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test.
    Maccario M; Gauna C; Procopio M; Di Vito L; Rossetto R; Oleandri SE; Grottoli S; Ganzaroli C; Aimaretti G; Ghigo E
    J Endocrinol Invest; 1999 Jun; 22(6):424-9. PubMed ID: 10435851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
    Orio F; Palomba S; Colao A; Russo T; Dentico C; Tauchmanovà L; Savastano S; Nappi C; Sultan C; Zullo F; Lombardi G
    J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced growth hormone response to L-dopa and pyridostigmine in obesity.
    Lee EJ; Kim KR; Lee KM; Lim SK; Lee HC; Lee JH; Lee DJ; Huh KB
    Int J Obes Relat Metab Disord; 1994 Jul; 18(7):465-8. PubMed ID: 7920871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of anorexiant drugs on growth hormone secretion in obese children.
    Baritussio A; Enzi G; Rigon G; Molinari M; Inelmen EM; Crepaldi G
    Pharmacol Res Commun; 1978 Jun; 10(6):529-40. PubMed ID: 693565
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.